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Human papillomavirus (HPV), a sexually transmitted infection and the etiologic cause of genital warts and cervical cancer, is
highly prevalent in sexually active men and women. Although cervical screening procedures have signiﬁcantly reduced the disease
burden associated with HPV infection, they are expensive and abnormal results cause signiﬁcant emotional distress. Therefore,
prevention may be an eﬀective strategyfor reducing the economic, psychosocial, anddisease burdenof HPVinfection. Multivalent
vaccines are now in clinical development. A bivalent vaccine that protects against HPV 16 and 18, and a quadrivalent vaccine
which protects against HPV types 6, 11, 16, and 18, have been shown to signiﬁcantly reduce the occurrence of incident and
persistent HPV infections in phase 2 clinical trials; phase 3 trials are currently underway. HPV vaccines will be most eﬀective
when administered prior to initiation of sexual activity, and vaccination campaigns should aggressively target preadolescent and
adolescent populations.
Copyright © 2006 David Soper. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
SIGNIFICANCE OF HPV INFECTION
Human papillomavirus (HPV) is the most common newly
acquired sexually transmitted infection (STI) in the United
States, with an estimated 20 million people infected [1]. Fur-
thermore, incidence of HPV infection has increased during
the past two decades, with approximately 6.2 million newly
diagnosedcasesannually[1,2](Figure 1).HPVinfectionhas
a very high prevalence rate in adolescent girls and young
women. One study showed that 36% of women 25 years of
age or younger are HPV-positive compared with less than
3% of women 45 years of age and older [3]. HPV is the etio-
logic agent of several genital epithelial lesions including gen-
ital warts (condylomata acuminata), cervical intraepithelial
neoplasia (CIN), and cervical cancer. Consequently, HPV is
a major public health burden.
More than 100 diﬀerent types of HPV have been identi-
ﬁed [4, 5]( Table 1). Low-risk types, HPV 6 and HPV 11, are
the most common types implicated in causing genital warts
[6]. Furthermore, due to their ability to cause low-grade cer-
vical lesions, infection with low-risk HPV types is often as-
sociated with abnormal Papanicolaou (Pap) test results [7].
Although genital warts are medically benign, and low-grade
CIN can spontaneously regress, diagnosis of genital warts or
an abnormal Pap smear result can cause emotional distress
and impose an economic burden [8].
In contrast to infection with HPV types 6 and 11, infec-
tion with high-risk HPV types 16 and 18 can lead to anogen-
ital cancers. HPV types 16 and 18 cause 70% of all cases of
cervicalcancer,withhalfofallcervicalcancerscausedbytype
16 alone [4]. Persistent infection with high-risk HPV types is
implicated in 99.7% of cervical cancers [9]. Preventing in-
fection with the most common low-risk and high-risk HPV
typeswouldpreventthemajorityofcasesofgenitalwartsand
cervical cancer, respectively.
The transmission typically occurs through the skin-to-
skinanogenitalcontact.IncreasedriskforacquiringHPVhas
been associated with multiple sexual partners, younger age
of sexual debut, failure to use condoms, and sex with un-
circumcised males [10]. However, one study reported that
20% of women became infected with only one lifetime sex
partner, suggesting that both partners must be sexually na¨ ıve
to prevent infection [10]. Several studies have shown that
the risk of infection increases substantially when initiating
a new sexual relationship [5, 10–13]. The transmission of
HPV infection can be blocked by latex condoms if the in-
fected area is physically covered [14]. Nonetheless, HPV of-
ten manifests on external anogenital sites not covered by a
condom, and so the latter does not prevent all infections.
However, the use of a condom may reduce HPV persistence
and therefore aid in the regression of HPV-associated le-
sions [15].2 Infectious Diseases in Obstetrics and Gynecology
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Figure 1: Estimated incidence of sexually transmitted infections in the United States [1].
Table 1: Common HPV types associated with HPV-related diseases [4].
HPV types Manifestations
High-risk 16, 19, 31, 33, 45
Low-grade cervical changes
High-grade cervical changes
Cervical cancer
Anogenital and other cancers
Low-risk 6, 11 Benign low-grade cervical changes
Condylomata acuminata (genital warts)
ECONOMIC BURDEN OF HPV INFECTION
Annual cervical cancer screening is expensive. In a study of
women enrolled in a USA health care plan, it was estimated
that an average of $26,415 per 1000 women was spent on an-
nual cervical screening and treatment for HPV-related dis-
eases [16]. When these data are extrapolated to the general
USA population, it can be estimated that $3.4 billion is spent
annually on diagnosis and treatment of HPV infection and
its associated cervical diseases [16]. Approximately 90% of
the estimated cost can be attributed to strategies for preven-
tion of cervical cancer, such as treatment of precancerous le-
sions and routine Pap tests, whereas the other 10% is spent
on treatment of cervical cancer (Figure 2)[ 16].
HPV infection is most prevalent in adolescents and
young adults, and this group also incurs the majority of
HPV-associated health care costs. When it comes to HPV-
related health care, women in the 20–29 year age group in-
curred an annual cost of $51,863 per 1000 women [16]. The
estimated lifetime total medical cost of HPV infection for
men and women aged 15–24 is $2.9 billion, which makes
HPV the second most expensive STI after HIV [17]. In ad-
dition, when the cost of treating genital warts is analyzed by
itself, it becomes apparent that this too causes a substantial
economic burden. Based on an incidence of 500,000 cases of
HPV infection per year, the annual total direct medical cost
for treatment of anogenital warts in all age groups for the
year 2000 was $167.4 million [17].
PROPHYLACTIC VACCINES: A PREVENTATIVE
STRATEGY FOR HPV INFECTION
Assembly of infectious virus, a necessary step in the HPV life
cycle, involves the formation of the capsid, or outer layer, of
the virion. The capsid is composed of two proteins, L1 and
L2, which are expressed later in infection. The major capsid
protein L1 comprises the outermost layer of the capsid and is
necessary for virus structure [18]. HPV vaccine development
has been considerably advanced due in part to the produc-
tion of virus-like particles (VLPs). “HPV-like” VLPs, which
mimic the structure of the HPV virion but do not contain
genetic material and can be manufactured by exogenous ex-
pression of L1 in a variety of cell types, including bacterial,
yeast, insect, and mammalian cells [18, 19]. VLPs are non-
infectious and nononcogenic, making them ideal candidates
for use in HPV vaccine production. VLPs are puriﬁed, con-
centrated, distributed into aliquots, and combined with an
adjuvant [20].
Early studies with a monovalent vaccine against HPV
16 have shown that VLP vaccines induce a strong immune
response against L1 in animal models [21, 22]a n dh u -
moral immunity in humans [23]. Other trials demonstrated
that booster doses of VLP vaccines induced protective levels
of antibodies [23–25]. Furthermore, in a proof-of-principle
study, the HPV 16 VLP vaccine was safe, well tolerated, and
induced antibody titers to levels signiﬁcantly higher those
producedinresponsetonaturalinfection[26].AlthoughthisDavid Soper 3
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Figure 2:AveragehealthcarecostsofcervicalHPVinfection[16]. ∗Averageageadjustedtothe1998USfemalepopulation;allcostestimates
were converted to 2002 dollars; ASC = atypical squamous cells; AGC = atypical glandular cells; LSIL = low-grade squamous intraepithelial
lesion; HSIL = high-grade squamous intraepithelial lesion.
study was not suﬃciently powered to assess vaccine eﬃcacy
in preventing clinical disease, vaccine recipients developed
fewer cervical lesions than placebo recipients. In addition,
the vaccine was 100% eﬀective in preventing persistent in-
fection, suggesting that VLP vaccines may help reduce the
incidence of cervical cancer precursors and invasive cervi-
cal cancer [26]. Similar results have been reported with other
monovalent VLP vaccines [27–29].
Immune responses to HPV infection are type-speciﬁc;
therefore, vaccine eﬃcacy can be greatly improved by com-
bining VLPs from several types of HPV into one multivalent
vaccine.Multivalentvaccinesthatoﬀerprotectionagainstthe
most common disease-causing HPV types are in late stages
of clinical development. Currently, a bivalent vaccine that
protects against 2 high-risk HPV types, and a quadrivalent
vaccine that protects against 2 high-risk and 2 low-risk HPV
types are being tested.
To determine the eﬃcacy, immunogenicity, and safety of
abivalentvaccinecontainingHPVtypes16and18,adouble-
blind, placebo-controlled phase 2 trial was conducted on
1113 women (15–25 years old) with no prior history of HPV
infection and normal cervical cytology [30]. In this study,
women received intramuscular injections of vaccine (20µg
of each VLP plus adjuvant) or placebo (adjuvant alone) on
day 1, at month 1, and at month 6, and then followed for
at least 17 months. The bivalent HPV 16/18 vaccine was
well tolerated, produced no vaccine-related serious adverse
events, and induced a major humoral immune response to
both HPV types. Furthermore, the vaccine was 90% eﬃca-
cious at reducing incident infection and 100% eﬃcacious at
preventing persistent infection [30].
Including additional HPV types in vaccines would be ex-
pected to cumulatively reduce HPV-associated disease bur-
den by preventing additional HPV infections. A quadriva-
lentvaccinehasbeendevelopedtoprotectagainstHPVtypes
6, 11, 16, and 18. A double-blind, placebo-controlled phase
2s a f e t ya n de ﬃcacy trial was conducted on more than 500
women aged 16–23 years. Women who were enrolled in the
trial received either the quadrivalent vaccine (20µge a c ho f
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Figure 3: Incidence of infection or disease associated with HPV 6,
11, 16, or 18 after vaccination with a quadrivalent vaccine versus
placebo (∗reported as incidence per 100 women-year at risk) [31].
HPV 6 and 18 VLP, and 40µg each of HPV 11 and 16 VLP
plus adjuvant) or placebo (adjuvant alone) on day 1, month
2, and month 6, and then were followed for 36 months [31].
Results of this trial showed that the quadrivalent vaccine was
well tolerated, produced few serious adverse events (none of
which were judged to be related to the vaccine), and stim-
ulated the production of antibodies directed against all four
HPV types. Furthermore, the vaccine reduced persistent in-
fection in vaccine recipients by 89% and prevented 100% of
clinical disease associated with HPV types 6, 11, 16, and 18
(Figure 3). Similarly high eﬃcacy results were reported for a
cohortofwomenwhodidnotadherecompletelytothestudy
protocol [31].
Recently, data from the phase 3 Females United to Uni-
versally Reduce Endo-ectocervical disease (FUTURE II) clin-
ical trial were presented. The quadrivalent HPV vaccine was
100% eﬀective at preventing CIN 2/3, AIS, and cervical can-
cer associated with HPV 16 or 18 infection during two years
of follow-up. The vaccine was well-tolerated and there were
no vaccine-related serious adverse events [32].
PUBLIC HEALTH BENEFITS OF HPV VACCINATION
Vaccines that provide protection against the most common
disease-causingHPVtypeswouldbeexpectedtosigniﬁcantly4 Infectious Diseases in Obstetrics and Gynecology
reduce the incidence of HPV-associated diseases. Reducing
HPV-associated disease burden may also reduce the health
care costs associated with these diseases.
Although HPV vaccines are not currently available to the
public, their potential public health beneﬁts have been re-
ported in several mathematical modeling studies [33–35].
Sanders et al reported that if a hypothetical vaccine that was
75% eﬃcacious at preventing high-risk HPV infection were
administered to approximately two million 12-year-old girls,
it would prevent 224,255 HPV infections, 3317 cases of can-
cer, and 1340 cervical cancer-associated mortalities in the
girls’ lifetimes [33]. Another study predicted that an HPV
16/18 vaccine would reduce the number of cervical cancer
cases associated with the HPV 16 and HPV 18 by 95% [34].
Mathematical modeling and sexual transmission data have
also suggested that both sexes should be vaccinated to pro-
vide the greatest reductions in HPV infections. For example,
onepopulation-levelstudypredictedthatafemale-onlyHPV
vaccination program would be only 68% as eﬀective in re-
ducing HPV prevalence as a program aimed at vaccinating
both men and women [35].
Genital warts and abnormal Pap tests can also produce
anxiety and emotional distress. In fact, diagnosis with genital
warts is often the most anxiety-provoking outcome of HPV
infection [36]. Because vaccination has shown promising re-
sults in the reduction of the disease burden associated with
HPV infection, it would be expected to reduce some of the
psychosocial and emotional burden as well.
A number of obstacles will need to be overcome to max-
imize the public health beneﬁts of HPV vaccination. Vacci-
nation programs must identify appropriate candidates for
vaccination, establish booster requirements, and overcome
potential individual, parental, and social barriers to HPV
vaccine acceptance. For example, individuals may view ac-
ceptance of HPV vaccines as admitting to risky sexual be-
havior. Furthermore, research has shown that knowledge
about HPV, an infection that many people know little about,
is directly correlated to vaccine acceptance [37–39]. Par-
ents may feel that their child is not at risk, or that vacci-
nation would support teenage sex or encourage risky sex-
ual behavior (ie, reduced condom use). Societal and cul-
tural issues may include beliefs that sexually transmitted dis-
eases are a deterrent or punishment for non-marital sex-
ual behavior. Alternatively, many people distrust medical
technology and are generally opposed to vaccines. Each
of these obstacles can be overcome by widespread eﬀorts
to educate individuals and society about the prevalence
of HPV and the risks associated with forgoing vaccina-
tion.
Administering HPV vaccines to populations prior to ini-
tiating sexual activity will yield the greatest health beneﬁt.
Because preadolescent and adolescent children are gener-
ally sexually na¨ ıve and develop robust immune responses
to vaccines, vaccinating young adolescents is predicted to
signiﬁcantly reduce the incidence of HPV infection and
HPV-associated diseases. In order to foster broad acceptance
of HPV vaccine, public health initiatives will need to educate
parents/caregivers as well as health care professionals about
the risks associated with HPV infection and the beneﬁts of
vaccination.
CONCLUSIONS
Vaccination has been widely accepted as an eﬀective means
by which infectious diseases can be prevented or eliminated.
VLP vaccines that protect against infection with the most
common disease-causing HPV types are currently in clini-
cal development and early reports have suggested that HPV
vaccines are highly eﬃcacious in preventing HPV infection
and HPV-associated disease. HPV vaccines will be most ef-
fective when administered prior to initiation of sexual activ-
ity and vaccination initiatives will most likely target preado-
lescent and adolescent populations.
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